Altor , , An Indirect Wholly-Owned Su Patent-Cliff Exposure & CMS Drug Spending Portfolio

Altor , , An Indirect Wholly-Owned Su (US): 1 reconciled FDA prescription therapies, $2.9M 2024 CMS Part D & Medicaid spend, and $35,800 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies1
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE DateMulti-asset schedule
2024 CMS Total Public Spend$2.9M
2024 Medicare Part D Spend$2.9M
2024 Medicaid Spend$0
California HCAI SB 17 FilingsSpecialty launch notice ($35,800 intro WAC)